FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000082450> ?p ?o ?g. }

• W3000082450 abstract "ABSTRACT Background The reversible EGFR tyrosine kinase inhibitors E and G are effective treatments for advanced NSCLC, but most pts acquire resistance. Currently, the benefit from sustained EGFR blockade during subsequent salvage therapy is unclear. LUX-Lung 5 is an international, multicenter phase III trial studying the efficacy of BIBW2992 (Afatinib®, A), an irreversible erbB family blocker, in NSCLC pts progressing after treatment with ctx and E or G irrespective of their EGFR mutation status. Here we report the outcome of NSCLC pts treated within LUX-Lung 5 at a single center in relation to EGFR and KRAS mutation status. Methods Pts with stage IV (UICC 7) NSCLC progressing after ctx and E or G were enrolled into LUX-Lung 5. In part A of the study pts received A (starting dose 50 mg/d) until progression. In part B pts with clinical benefit ≥12 wks were randomized between A plus weekly paclitaxel vs investigator's choice mono ctx. Following microdissection, tumor DNA was extracted and analyzed by PCR and Sanger sequencing. Results Between May 2010 and February 2011 39 pts (20 f, 19 m; median age 61 y, 38-83 y) were enrolled at the West German Cancer Center. Median number of pretreatments was 3 (1-8) including E or G. So far, tumor biopsies were retrieved from 25 pts (64%). Somatic EGFR mutations were detected in 11 pts (44% of analyzed tumors, 28% of entire cohort), whereas 14 pts (56%/36%) exhibited EGFR wild type (wt) sequences. EGFR mutation status remains unknown in 14 pts (36%). KRAS mutation analysis was performed in 20 pts (51% of entire cohort) and 4 mutations were observed (20%/10%), 3 in EGFR wt and one in an EGFR mutant tumor. Median survival time from initiation of A was 432 d in EGFR mutant pts, 189 d in EGFR wt pts, and 255 d in KRAS mutant pts. Median survival time of pts with unknown EGFR mutation status was 191 d. Safety of A was manageable. Conclusions A can achieve disease control in heavily pretreated NSCLC pts. Pts with EGFR mutant tumors experience prolonged survival as compared to EGFR wt tumors (HR 0.29; 95% CI 0.07–0.64; p = 0.0058). This argues for sustained tumor dependency on EGFR signaling despite progression after E or G. Disclosure J. Kohler: J. Kohler received financial support from Boehringer Ingelheim for writing a review article. T.C. Gauler: T.C. Gauler is principle investigator of the BI1200.43 trial testing Afatinib in HNSCC. D. Theegarten: D. Theegarten is member of the Lilly Advisory Board. W. Eberhardt: W. Eberhardt received honoraries for advisory board functions from Boehringer Ingelheim, Astra Zeneca, Roche, OSi Pharmaceuticals, Pfizer and honoraries for lectures from Boehringer Ingelheim, Astra Zeneca, Roche and Pfizer. M. Schuler: M. Schuler received research funding from Boehringer Ingelheim and travel support from Lilly. All other authors have declared no conflicts of interest." @default.
• W3000082450 created "2020-01-23" @default.
• W3000082450 creator A5010366885 @default.
• W3000082450 creator A5012866504 @default.
• W3000082450 creator A5023684301 @default.
• W3000082450 creator A5026512515 @default.
• W3000082450 creator A5034451063 @default.
• W3000082450 creator A5036507802 @default.
• W3000082450 creator A5045856144 @default.
• W3000082450 creator A5047006205 @default.
• W3000082450 creator A5073234708 @default.
• W3000082450 creator A5075896912 @default.
• W3000082450 date "2012-09-01" @default.
• W3000082450 modified "2023-09-28" @default.
• W3000082450 title "Impact of EGFR Mutation Status on Clinical Benefit from BIBW 2992 in Patients (PTS) with Advanced Non-Small Cell Lung Cancer (NSCLC) Progressing After Chemotherapy (CTX) and Erlotinib (E) or Gefitinib (G) – A Single Center Experience" @default.
• W3000082450 doi "https://doi.org/10.1016/s0923-7534(20)33801-1" @default.
• W3000082450 hasPublicationYear "2012" @default.
• W3000082450 type Work @default.
• W3000082450 sameAs 3000082450 @default.
• W3000082450 citedByCount "0" @default.
• W3000082450 crossrefType "journal-article" @default.
• W3000082450 hasAuthorship W3000082450A5010366885 @default.
• W3000082450 hasAuthorship W3000082450A5012866504 @default.
• W3000082450 hasAuthorship W3000082450A5023684301 @default.
• W3000082450 hasAuthorship W3000082450A5026512515 @default.
• W3000082450 hasAuthorship W3000082450A5034451063 @default.
• W3000082450 hasAuthorship W3000082450A5036507802 @default.
• W3000082450 hasAuthorship W3000082450A5045856144 @default.
• W3000082450 hasAuthorship W3000082450A5047006205 @default.
• W3000082450 hasAuthorship W3000082450A5073234708 @default.
• W3000082450 hasAuthorship W3000082450A5075896912 @default.
• W3000082450 hasBestOaLocation W30000824501 @default.
• W3000082450 hasConcept C121608353 @default.
• W3000082450 hasConcept C126322002 @default.
• W3000082450 hasConcept C143998085 @default.
• W3000082450 hasConcept C2776232967 @default.
• W3000082450 hasConcept C2776256026 @default.
• W3000082450 hasConcept C2777930144 @default.
• W3000082450 hasConcept C2778087573 @default.
• W3000082450 hasConcept C2779177807 @default.
• W3000082450 hasConcept C2779422266 @default.
• W3000082450 hasConcept C2779438470 @default.
• W3000082450 hasConcept C2780580887 @default.
• W3000082450 hasConcept C2780586478 @default.
• W3000082450 hasConcept C2781187634 @default.
• W3000082450 hasConcept C526805850 @default.
• W3000082450 hasConcept C71924100 @default.
• W3000082450 hasConcept C81729549 @default.
• W3000082450 hasConceptScore W3000082450C121608353 @default.
• W3000082450 hasConceptScore W3000082450C126322002 @default.
• W3000082450 hasConceptScore W3000082450C143998085 @default.
• W3000082450 hasConceptScore W3000082450C2776232967 @default.
• W3000082450 hasConceptScore W3000082450C2776256026 @default.
• W3000082450 hasConceptScore W3000082450C2777930144 @default.
• W3000082450 hasConceptScore W3000082450C2778087573 @default.
• W3000082450 hasConceptScore W3000082450C2779177807 @default.
• W3000082450 hasConceptScore W3000082450C2779422266 @default.
• W3000082450 hasConceptScore W3000082450C2779438470 @default.
• W3000082450 hasConceptScore W3000082450C2780580887 @default.
• W3000082450 hasConceptScore W3000082450C2780586478 @default.
• W3000082450 hasConceptScore W3000082450C2781187634 @default.
• W3000082450 hasConceptScore W3000082450C526805850 @default.
• W3000082450 hasConceptScore W3000082450C71924100 @default.
• W3000082450 hasConceptScore W3000082450C81729549 @default.
• W3000082450 hasLocation W30000824501 @default.
• W3000082450 hasOpenAccess W3000082450 @default.
• W3000082450 hasPrimaryLocation W30000824501 @default.
• W3000082450 isParatext "false" @default.
• W3000082450 isRetracted "false" @default.
• W3000082450 magId "3000082450" @default.
• W3000082450 workType "article" @default.